## Core Concept
Dihydroergotamine and ergotamine are both ergot alkaloids used in the treatment of migraine and other vascular headaches. They act as **5-HT1 receptor agonists** and have **vasoconstrictive properties**. The key difference lies in their pharmacokinetic properties and receptor affinity.

## Why the Correct Answer is Right
Dihydroergotamine has a higher affinity for **5-HT1D receptors** compared to ergotamine. This results in a more potent effect on these receptors, which are involved in the pathophysiology of migraine. Additionally, dihydroergotamine has a **greater ability to penetrate the central nervous system** due to its pharmacokinetic profile.

## Why Each Wrong Option is Incorrect
* **Option A:** This option is incorrect because both dihydroergotamine and ergotamine have vasoconstrictive effects; the distinction does not primarily lie in their vascular effects.
* **Option B:** This option is incorrect as both compounds do have effects on serotonin receptors; however, dihydroergotamine's specific receptor affinity profile differs.
* **Option C:** This option might seem plausible, but without specific context on pharmacokinetics or receptor affinity, it's hard to directly refute; however, the main distinction usually cited involves receptor affinity and central nervous system penetration.

## Clinical Pearl / High-Yield Fact
A key clinical point to remember is that **dihydroergotamine is often administered intravenously** for the treatment of severe migraine attacks, especially in an acute setting. Its **rapid onset of action** makes it useful for this purpose.

## Correct Answer: B.